Skip to Content


Active Substance: zaleplon
Common Name: zaleplon
ATC Code: N05CF03
Marketing Authorisation Holder: Meda AB
Active Substance: zaleplon
Status: Withdrawn
Authorisation Date: 1999-03-12
Therapeutic Area: Sleep Initiation and Maintenance Disorders
Pharmacotherapeutic Group: Psycholeptics

Therapeutic Indication

Zerene is indicated for the treatment of patients with insomnia who have difficulty falling asleep. It is indicated only when the disorder is severe, disabling or subjecting the individual to extreme distress.

The marketing authorisation for Zerene has been withdrawn at the request of the marketing-authorisation holder.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.